MENU
Showcases Stock ranks Forex

Bristol-Myers Squibb Company (BMY)
46.925  0.085 (0.18%) 06-20 15:04
Open: 46.92 Pre. Close: 46.84
High: 47.39 Low: 46.72
Volume: 8,639,546 Market Cap: 95,496(M)
Stock Technical Analysis
Overall:     
Target: Six months: 56.45
One year: 59.28
Support: Support1: 44.42
Support2: 36.96
Resistance: Resistance1: 48.33
Resistance2: 50.75
Pivot: 48.58
Moving Averages: MA(5): 47.91
MA(20): 48.22
MA(100): 53.48
MA(250): 52.36
MACD: MACD(12,26): -0.21
Signal(12,26,9): -0.12
%K %D: %K(14,3): 16.62
%D(3): 33.04
RSI: RSI(14): 41.95
52-Week: High: 63.33
Low: 39.35
Change(%): 14.7
Average Vol(K): 3-Month: 14424
10-Days: 10215
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 47.441 - 47.773 47.773 - 48.027
Low: 45.519 - 45.971 45.971 - 46.317
Close: 46.216 - 46.827 46.827 - 47.296
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ BMY ] has closed above bottom band by 16.1%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Stock chart
Stock News
Wed, 18 Jun 2025
Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus

Wed, 18 Jun 2025
Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - simplywall.st

Wed, 18 Jun 2025
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus

Wed, 18 Jun 2025
Bristol Myers Squibb Announces Dividend - June 17, 2025 - BioSpace

Tue, 17 Jun 2025
Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - Insider Monkey

Mon, 16 Jun 2025
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers - General
Shares Out. (M) 2040.00
Shares Float (M) 2030.00
% Held by Insiders 0.07
% Held by Institutions 82.23
Shares Short (K) 37010
Shares Short Prior Month (K) 30030
Stock Financials
EPS 2.680
Book Value (p.s.) 8.550
Profit Margin 11.38
Operating Margin 31.57
Return on Assets (ttm) 7.2
Return on Equity (ttm) 32.0
Qtrly Rev. Growth -5.6
Gross Profit (p.s.) 17.441
Sales Per Share 23.353
EBITDA (p.s.) 9.397
Qtrly Earnings Growth
Operating Cash Flow (M) 14310.00
Levered Free Cash Flow (M) 13930.00
Stock Valuation
PE Ratio 17.56
PEG Ratio
Price to Book value 5.50
Price to Sales 2.01
Price to Cash Flow 6.71
Stock Dividends
Dividend 0.620
Dividend Yield 0.01
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android